Which feature best distinguishes sulfonylureas from meglitinides in their mechanism of action and clinical use?

Explanation

## Distinguishing Sulfonylureas from Meglitinides ### Mechanism of Action Both drug classes stimulate insulin secretion by binding to ATP-sensitive potassium channels (K~ATP~) on pancreatic beta cells. However, their **kinetics and selectivity differ markedly**. | Feature | Sulfonylureas | Meglitinides | |---------|---------------|---------------| | **Onset** | Slow (hours) | Rapid (minutes) | | **Duration** | Long (8–24 hrs) | Short (3–4 hrs) | | **Insulin pattern** | Sustained, non-physiologic | Pulsatile, mimics postprandial response | | **Hypoglycemia risk** | High (esp. nocturnal) | Lower (short duration) | | **Clinical use** | Fasting hyperglycemia | Postprandial hyperglycemia | | **Dosing** | Once or twice daily | Before meals (3× daily) | ### Key Pharmacokinetic Difference **Key Point:** Sulfonylureas have a long half-life (glibenclamide ~10 hrs, glipizide ~4–6 hrs) and cause **sustained, non-physiologic insulin secretion**, leading to a high risk of **nocturnal and fasting hypoglycemia**. Meglitinides (repaglinide, nateglinide) are rapidly absorbed and metabolized (half-life 1–3 hrs), producing a **rapid, short-lived insulin pulse** that mirrors the normal postprandial response. ### Clinical Implications **High-Yield:** The **duration of action and hypoglycemia profile** is the best discriminator: - **Sulfonylureas:** Longer acting → suitable for fasting hyperglycemia control but higher nocturnal hypoglycemia risk. - **Meglitinides:** Shorter acting → ideal for postprandial glucose spikes in patients who skip meals or have variable meal timing; lower overall hypoglycemia risk. **Clinical Pearl:** A patient on sulfonylureas who develops nocturnal hypoglycemia is a classic presentation; switching to meglitinides (or DPP-4 inhibitors) often resolves this without loss of glycemic control. ### Why Option 3 is Correct Option 3 captures both the **duration difference** (longer for sulfonylureas, shorter for meglitinides) and the **clinical consequence** (nocturnal hypoglycemia risk with sulfonylureas; postprandial suitability for meglitinides). This is the most clinically relevant and exam-tested discriminator.